omniture
映恩生物DUALITYBIO

Latest News

DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors

SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinic...

2023-08-07 18:00 1324

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcend...

2023-01-05 09:00 1294

Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics...

2022-12-15 21:00 1666

Duality announced the appointment of Dr. Yver as Chairman of SAB

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics,...

2022-10-03 22:00 1615

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (Dua...

2021-05-20 08:00 1607